Table 1 ERβ and clinical outcome
ERβ isoform | ERβ expression | ERα status | Number of patients | Clinical outcome | Year (Ref.) |
|---|---|---|---|---|---|
ERβ | ↑ | – | 1400 | reduced RFS | 2018 [51] |
ERβ |  |  | 32 | worse prognosis | 2017 [46] |
ERβ | ↑ | +/− | 1026 | better prognosis | 2017 [30] |
ERβ | ↑ |  | 120 | worse prognosis | 2017 [44] |
ERβ |  | – | 17 | no association with PFS | 2016 [52] |
ERβ | ↑ | + | 195 | reduced DFS; reduced DFS after endocrine therapy | 2016 [49] |
Nuclear ERβ1 |  | – | 126 | no association with DFS and OS | 2015 [53] |
ERβ | ↑ | + | 127 | no association with PFS | 2015 [54] |
ERβ | ↑ | – | 107 | reduced DFS | 2015 [54] |
Nuclear ERβ1 | ↑ | – | 19 | reduced OS | 2015 [55] |
ERβ1 |  | – | 571 | prolonged OS, DFS, and DMFS | 2015 [56] |
ERβ | ↑ | +/− | 583 | worse prognosis; worse endocrine therapy response | 2014 [48] |
ERβ | ERα/ERβ: 1–1.5 | 78 | better hormonal treatment response | 2013 [45] | |
ERβ | ↓ |  | 89 | reduced OS | 2012 [47] |
Nuclear ERβ1 | ↑ | +/− | 123 | better chemotherapy therapy and endocrine therapy response | 2011 [50] |
Cytoplasmic ERβ 2/cx |  | +/− | 123 | poor chemotherapy response | 2011 [50] |
ERβ | ↓ |  | 41 | prolonged PFS; better aromatase inhibitor therapy response | 2010 [57] |
Nuclear P-S105-ERβ | ↑ | +/− | 459 | better prognosis | 2010 [58] |